Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupixent in CRSwNP with S. aureus colonization
NCT05094570Phase 4Recruiting
- Sponsor
- University of Virginia
- Start
- Sep 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in chronic rhinosinusitis with nasal polyposis (CRSwNP), sponsored by University of Virginia. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyposis (CRSwNP)
Beyond the preview
Go deeper on NCT05094570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05094570.